Dépression résistante : les stratégies de potentialisation

Lithium is among the most classically recommended add-on therapeutic a strategy for the management of depressive patients showing unsuccessful a response to standard antidepressant medications. a The effectiveness of the add-on strategy with lithium requires achieving a plasma levels above 0.5 mEq/L. a Mood-stabilizing antiepileptic drugs such as carbamazepine, valproate a derivatives or lamotrigine have not demonstrated conclusive therapeutic a effects for the management of depressive patients showing unsuccessful a response to standard antidepressant medications. a Thyroid hormones are considered among the currently recommended add-on a therapeutic strategy for the management of depressive patients showing a unsuccessful response to standard antidepressant medications. a The effectiveness of the add-on strategy with thyroid hormones requires a achieving plasma concentration of TSH close to the lower limits at the a normal range (0.4 mUI/L) or even below it. Second-generation a antipsychotics such as aripiprazole or quetiapine have consistently a demonstrated significant therapeutic effects for the management of a depressive patients showing unsuccessful response to standard a antidepressant medications. a Second-generation antipsychotics however require the careful monitoring a of both cardiovascular and metabolic adverse effects.